Impact of antipsychotics on geriatric patients: Efficacy, dosing, and compliance

Primary Care Companion to the Journal of Clinical Psychiatry

Volumn 2, Issue 5, 2000, Pages 165-172

  Maguire, Gerald A ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 16244390441     PISSN: 15235998     EISSN: None     Source Type: Journal    
DOI: 10.4088/pcc.v02n0503     Document Type: Article

References (35)

1. Hobbs FB. 65+ In the United States. US Department of Commerce: Economie and Statistics Administration. Washington, DC: US Bureau of the Census; 1996
2. American Psychiatrie Association Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition. Washington, DC: American Psychiatric Association; 1994
3. Ferris SH, Steinberg G, Shulman E, et al Institutionalization of Alzheimer's patients: reducing precipitating factors through family counseling. Arch Found Thanatol 1985;12:7
4. Forsyth E, Ritzline PD. An overview of the etiology, diagnosis, and treatment of Alzheimer disease. Phys Ther 1998;78:1325-1331
5. Reisberg B. Alzheimer's disease. In: Sadavoy J, ed, Comprehensive Review of Geriatric Psychiatry II. 2nd ed. Washington, DC: American Psychiatric Press; 1996:401-458
6. Brumback RA, Leech RW. Alzheimer's disease: pathophysiology and the hope for therapy. J Okla State Med Assoc 1996;87:103-111
7. Jorm AF, Korten AE, Henderson AS. The prevalence of dementia: a quantitative integration of the literature. Acta Psychiatr Scand 1987;76: 465-179
8. Tariot PN. Treatment strategies for agitation and psychosis in dementia. J Clin Psychiatry 1996;57(suppl 14):21-29
9. Snow C. Medicare HMOs develop plan for future of Alzheimer's disease programming. Modern Healthcare 1996;26(39):67-70
10. Schumock GT. Economic considerations in the treatment and management of Alzheimer's disease. Am J Health Syst Pharm 1998;55(suppl 2): S17-S21
11. Verma SD, Davidoff DA, Kambhampati KK. Management of the agitatedelderly patient in the nursing home: the role of the atypical antipsychotics. J Clin Psychiatry 1998;59(suppl 19):50-55
12. Saltz BL, Woerner MG, Kane JM, et al. Prospective study of tardive dyskinesia incidence in the elderly. JAMA 1991; 266:2402-2406
13. Arnt J, Skarsfeldt T. Do novel antipsychotics have similar pharmacological characteristics? a review of the evidence. Neuropsychopharmacology 1998;18:63-101
14. Sweet RA, Pollock BG. New atypical antipsychotics: experience and utility in the elderly. Drugs Aging 1998;12:115-127
15. Leucht S, Pitschel-Walz G.Abraham D, et al. Efficacy and extrapyramidal side effects of the new antipsychotics olanzapine, quetiapine, risperidone, and sertindole compared to conventional antipsychotics and placebo: a meta-analysis of randomized controlled trials. Schizophr Res 1999;35: 51-68
16. Katz IR, Jeste.-DV, Mintzer JE, et al. Comparison of risperidone and placebo for psychoses and, behavioral disturbances associated with dementia: a randomized, double blind trial. J Clin Psychiatry 1999;60:107-115
17. Lavretsky H, Sultzer D. A structured trial of risperidone for the treatment of agitation in dementia Am J Geriatr Psychiatry 1998;6:127-135
18. Lane LM, Burns PR, Sanger TM, et al. Olanzapine in the treatment of elderly patients with schizophrenia and related psychotic disorders. Presented at the 11th Congress of the European College of Neuropsychopharmacology (ECNP); Oct 31-Nov 4 1998; Paris, France
19. Street J, Clark WS, Milan S, et al. Olanzapine in the treatment of psychosis and behavioral disturbances associated with Alzheimer's disease. Arch Gen Psychiatry. In press
20. Peuskens J, Link CGG. A comparison of quetiapine and chlorpromazine in the treatment of schizophrenia. Acta Psychiatr Scand 1997;96:265-273
21. Arvanitis LA, Miller BG, and the Seroquel Trial 13 Study Group. Multiple fixed doses of Seroquel (quetiapine) in patients with acute exacerbation of schizophrenia: a comparison with haloperidol and- placebo. Biol Psychiatry 1997;42:233-246
22. Barnes TRE, McPhillips MA. Novel antipsychotics extrapyranydal. side effects and tardive dyskinesia. Int Clin Psychopharmacol 1998 13(suppl 3):S49-S57
23. Jeste DV, Eastham JH, Lacro JP, et al. Management of late-life psychosis. J Clin Psychiatry 1996;57(suppl 3):39-45
24. Beasley CM Jr, Dellva MA, Tamura RN, et al. Randomized double-blind comparison of the incidence of tardive dyskinesia in patients with schizophrenia during long-term treatment with olanzapine or haloperidol. Br J Psychiatry 1999;174:23-30
25. Tollefson GD, Beasley CM Jr, Tamura RN, et al. Blind, controlled, longterm study of the comparative incidence of treatment-emergent tardive dyskinesia with olanzapine or haloperidol. Am J Psychiatry 1997;154: 1248-1254
26. Parsa MA, Bastani B. Quetiapine (Seroquel) in the treatment of psychosis in patients with Parkinson's disease. J Neuropsychiatry Clin Neurosci 1998;10:216-219
27. Rich SS, Friedman JH, Ott BR. Risperidone versus clozapine in the treatment of psychosis in six patients with Parkinson's disease and other akinetic-rigid syndromes. J Clin Psychiatry 1995;56:556-559
28. Purdon SE, Jones BDW, Slip E, et al, for The Canadian Collaborative Group for Research on Cognition in Schizophrenia. Neuropsychological change in early phase schizophrenia during 12 months of treatment with olanzapine, risperidone, or haloperidol. Arch Gen Psychiatry 2000;57: 249-258
29. Sax KW, Strakowski SM, Keck PE Jr. Attentional improvement following quetiapine fumarate treatment in schizophrenia. Schizophr Res 1998;33: 151-155
30. Popli A, Gupta S, Rangwani SR. Risperidone-induced galactorrhea associated with a prolactin elevation. Ann Clin Psychiatry 1998;10:31-33
31. Shiwach RS, Carmody TJ. Prolactogenic effects of risperidone in male patients: a preliminary study. Acta Psychiatr Scand 1998;98:81-83
32. Fava M, Fava GA, Kellner R, et al. Psychosomatic aspects of hyperprolactinemia. Psychother Psychosom 1983;40:257-262
33. Cohen AI. Bromocriptine for prolactinoma-related dissociative disorder and depression [letter]. J Clin Psychopharmacol 1995;15:144-145
34. Tollefson GD, Beasley CM Jr, Tran PV, et al. Olanzapine versus haloperidol in the treatment of schizophrenia and schizoaffective and schizophreniform disorders: results of an international collaborative trial. Am J Psychiatry 1997;154:457-465
35. Tran PV, Hamilton SH, Kuntz AJ, et al. Double-blind comparison of olanzapine versus risperidone in the treatment of schizophrenia and other psychotic disorders. J Clin Psychopharmacol 1997;17:407-4l8